Indication
Purpura
7 clinical trials
6 products
3 drugs
Product
BI 655064Clinical trial
Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.Status: Terminated, Estimated PCD: 2016-04-26
Product
HMPL-523Clinical trial
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)Status: Completed, Estimated PCD: 2021-02-16
Product
BIVV009Clinical trial
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
IsatuximabClinical trial
The Combination of ATRA and Eltrombopag as the Treatment Strategy for Glucocorticoid-Resistant/Relapsed ITP Based on the Stratification of the New Biomarker MSC-C5b-9: A Prospective, Randomized, Open-Label, Multicenter Clinical TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Product
EltrombopagClinical trial
Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
DexamethasoneDrug
VarlilumabClinical trial
ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEaseStatus: Recruiting, Estimated PCD: 2025-01-01
Drug
Aspirin